NiKang Therapeutics is a clinical stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. NiKang's target selection is driven by deep insights into disease biology and molecular pathways. The Company's discovery approach is informed by target structure biology and capitalizes on structure-based drug design. The successful implementation of the company's strategy enables it to rapidly and efficiently discover and advance proprietary drug candidates with the most desirable pharmacological features into clinical studies. The company strives to bring transformative medicines to patients in need.